Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience

作者
Nikhil Kapila,K.V. Narayanan Menon,Kawtar Alkhalloufi,Jason M. Vanatta,Carla Murgas,Diego C. Reino,Samer S. Ebaid,Joshua Shaw,Neerja Agrawal,Salwa Rhazouani,Viviana Navas,Cedric Sheffield,Asad Ur Rahman,Michael Castillo,Christina C. Lindenmeyer,Charles M. Miller,Cristiano Quintini,Xaralambos Bobby Zervos
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:72 (1): 32-41 被引量:120
标识
DOI:10.1002/hep.31011
摘要

Background and Aims Hepatitis C virus (HCV)‐viremic organs are underutilized, and there is limited real‐world experience on the transplantation of HCV‐viremic solid organs into recipients who are HCV negative. Approach and Results Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educated and consented by protocol on the transplantation of HCV‐viremic organs. All recipients were HCV nucleic acid test and anti‐HCV antibody negative at the time of transplant and received an HCV‐viremic organ. The primary outcome was sustained virological response (SVR) at 12 weeks after completion of direct‐acting antiviral (DAA) therapy (SVR 12 ). Seventy‐seven patients who were HCV negative underwent solid organ transplantation from a donor who was HCV viremic. No patients had evidence of advanced hepatic fibrosis. Treatment regimen and duration were at the discretion of the hepatologist. Sixty‐four patients underwent kidney transplant (KT), and 58 KT recipients had either started or completed DAA therapy. Forty‐one achieved SVR 12 , 10 had undetectable viral loads but are not eligible for SVR 12 , and 7 remain on treatment. One KT recipient was a nonresponder because of nonstructural protein 5A resistance. Four patients underwent liver transplant and 2 underwent liver‐kidney transplant. Three patients achieved SVR 12 , 1 has completed DAA therapy, and 2 remain on treatment. Six patients underwent heart transplant and 1 underwent heart‐kidney transplant. Six patients achieved SVR 12 and 1 patient remains on treatment. Conclusions Limited data exist on the transplantation of HCV‐viremic organs into recipients who are HCV negative. Our study is the largest to describe a real‐world experience of the transplantation of HCV‐viremic organs into recipients who are aviremic. In carefully selected patients, the use of HCV‐viremic grafts in the DAA era appears to be efficacious and well tolerated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
王诗琪完成签到,获得积分10
2秒前
2秒前
miaomiao完成签到,获得积分20
2秒前
水煮电吹风的应助被心木采纳,获得10
2秒前
3秒前
阿狸完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
王诗琪发布了新的文献求助10
6秒前
bubu完成签到,获得积分10
7秒前
惠1发布了新的文献求助10
7秒前
111111完成签到,获得积分10
8秒前
9秒前
Elowen发布了新的文献求助30
10秒前
10秒前
友好绿草完成签到,获得积分10
10秒前
FG发布了新的文献求助10
11秒前
初一完成签到,获得积分10
11秒前
12秒前
元吉的应助被陈哈哈采纳,获得10
13秒前
molihuakai的应助被xwx采纳,获得10
15秒前
含糊的蘑菇完成签到,获得积分10
15秒前
maggie完成签到,获得积分10
15秒前
传奇3的应助被xiaolong采纳,获得10
15秒前
Raven发布了新的文献求助10
16秒前
青年才俊完成签到,获得积分10
16秒前
谷粱紫槐完成签到,获得积分10
16秒前
16秒前
wanci的应助被努力的扣扣酱采纳,获得10
17秒前
安静完成签到,获得积分10
17秒前
18秒前
li发布了新的文献求助10
19秒前
自然的湘完成签到,获得积分10
19秒前
秋风的应助被安静采纳,获得10
22秒前
22秒前
molihuakai的应助被安详的夜春采纳,获得10
23秒前
科研通AI6.3的应助被Liu采纳,获得30
23秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568